Pharmacological treatment of mild cognitive impairment as a prodromal syndrome of Alzheimer´s disease

• Verfasst von: Karakaya, Tarik [VerfasserIn]
• Verfasst von: Fußer, Fabian [VerfasserIn]
• Verfasst von: Schröder, Johannes [VerfasserIn]
• Verfasst von: Pantel, Johannes [VerfasserIn]
• Titel: Pharmacological treatment of mild cognitive impairment as a prodromal syndrome of Alzheimer´s disease
• Verf.angabe: Tarik Karakaya, Fabian Fußer, Johannes Schröder and Johannes Pantel
• E-Jahr: 2013
• Jahr: 1. Januar 2013
• Umfang: 7 S.
• Teil: volume:11
• Teil: year:2013
• Teil: number:1
• Teil: pages:102-108
• Teil: extent:7
• Fussnoten: Gesehen am 15.04.2021
• Titel Quelle: Enthalten in: Current neuropharmacology
• Ort Quelle: Hilversum [u.a.] : Bentham Science Publ., 2003
• Jahr Quelle: 2013
• Band/Heft Quelle: 11(2013), 1, Seite 102-108
• ISSN Quelle: 1875-6190
• DOI: doi:10.2174/157015913804999487
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1754985548

Abstract

Mild cognitive impairment (MCI) is a syndrome which, depending on various neurobiological, psychological and social factors, carries a high risk of developing into dementia. As far as diagnostic uncertainty and the heterogeneous underlying pathophysiological mechanisms are concerned, only limited therapeutic options are currently available. Clinical trials involving a wide range of substances have failed to show efficacy on primary and secondary outcome parameters. Most results reflect not only a lack of effectiveness of drug therapy but also methodological constraints in true prodromal Alzheimer´s disease (AD) based on clinical criteria. Biomarkers may help to identify MCI as a prodromal phase of dementia, so it is important to use them to improve specificity of case selection in future studies. For MCI as a prodromal syndrome of AD, clinical trials with disease modifying drugs that target underlying pathological mechanisms such as amyloid-beta accumulation and neurofibrillary tangle formation may help develop effective treatment options in the future. Alternative pharmacological approaches are currently being evaluated in ongoing phase 1 and phase 2 studies. Nevertheless, a lack of approved pharmacotherapeutic options has led to specific interventions that focus on patient education and life-style related factors receiving increasing attention.